Tuesday, 8 January 2008 - Tissera, Inc. (OTCBB: TSSR ) reports the achievement of a significant milestone in its ongoing large animal diabetic model experiments of pancreatic xenotransplantation , designed for the future treatment of insulin-dependent (type I) diabetes mellitus.Based on the previously reported positive results obtained in pancreatic transplantation experiments in normal non human primates, Tissera's sponsored research team at the Weizmann Institute of Science has moved forward to investigate in diabetic non human primates the functional and therapeutic value of the company's approach. In these studies, non human primates are treated by an agent called streptozotocin which induces them to become diabetic and consequently dependent upon administration of exogenous insulin for the maintenance of reasonable blood sugar levels. After allowing a few weeks for stabilization, appropriately timed pig embryonic pancreatic tissue is transplanted into the diabetic primate, which is thereafter intensively and carefully followed... Tissera's Press Release-
